New method enabling therapeutical targeting of lactate transporters
New method hat allowed the discovery of specific inhibitors of a lactate transporter that is associated with cancer
Scientists from the Giulio Superti-Furga Lab at CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, have developed a new method that allowed the discovery of specific inhibitors of a lactate transporter that is associated with cancer and other diseases areas. The compound identified in the assay system could provide a new starting point for cancer treatments. The study was now published in Cell Chemical Biology.
Transporter proteins, including their largest class, the solute carrier (SLC) family, are proteins that are mostly located in the cell membrane and through which the supply and removal of nutrients such as amino acids, sugars and nucleotides of a cell are handled. They are key players in cell metabolism and have an essential role in health and disease. Despite their vital physiological role and although they are considered attractive therapeutic targets, most SLCs have not yet been adequately studied pharmacologically. This is precisely what numerous scientists in the research group of Giulio Superti-Furga, Scientific Director at the CeMM the Research Center for Molecular Medicine of the Austrian Academy of Sciences and professor at the Medical University of Vienna, are working on. They have now developed a method to target lactate transporters SLC16A1 and SLC16A3, which are associated with certain cancers and other diseases.
Lactate, an end product of glycolysis, is known primarily as a metabolic waste product, but it is also used as an energy source. In fact, it has been shown that in many tissues, highly glycolytic cells secrete lactate, which is then used as an energy source by neighboring cells. This has been observed, for example, in skeletal muscle, brain, testes, and tumor microenvironment (TME). Lactate is transported across the membrane predominantly by members of the SLC16 family. Of four key lactate transporters, studies particularly attribute a central role to the SLC16A1 (MCT1) and SLC16A3 (MCT4) genes. Giulio Superti-Furga explains, “We know for more than a century that tumor cells tend to be highly glycolytic, and that the concentration of lactate can reach extreme levels inside tumors. But it is only relatively recently that we are starting to understand the consequences of this. For example, the high lactate levels are contributing to the suppression of immune cells inside the tumors, or to the development of resistances to treatment. Lactate transporters have a key role in this, especially SLC16A1 and SLC16A3, known as the major lactate importer and the major lactate exporter. Both transporters are considered promising drug targets.”
The study’s first author Vojtech Dvorak, PhD student in Superti-Furga’s lab, adds, “One of the major obstacles for the development of novel drugs that target SLCs are the frequent functional redundancies among several transporters that are present in cells. This makes it very difficult to isolate the impact of a potential drug candidate on a single transporter and hence determine the selectivity. In one of our previous projects, we found a synthetic lethality between SLC16A1 and SLC16A3 present in several cell models. That is, the cell normally has both transporters, and when one of them is either inhibited by the drug, or the gene for one of them is lost, the other transporter can compensate. However, when say, the SLC16A1 gene is lost, the cell then actually depends on SLC16A3 for its survival (and vice versa). We realized that we could create several cell lines that are dependent on either of the distinct lactate transporters and use them to search for highly selective drugs.”
In the study published in Cell Chemical Biology, the scientists describe the development of the assay system, called Paralog-dependent isogenic cell assay, or PARADISO for short, and it’s use to develop a highly selective chemical probe targeting SLC16A3, called slCeMM1. Superti-Furga concludes, “The lack of specific cell-based assays is a problem for many promising drug targets, not only for SLCs. The logic of the PARADISO assay system should be in principle widely applicable and help to find new therapeutic targets.”
Original publication
Vojtech Dvorak, Andrea Casiraghi, Claire Colas, Anna Koren, Tatjana Tomek, Fabian Offensperger, Andrea Rukavina, Gary Tin, Elisa Hahn, Sarah Dobner, Fabian Frommelt, Andras Boeszoermenyi, Viktoriia Bernada, J. Thomas Hannich, Gerhard F. Ecker, Georg E. Winter, Stefan Kubicek, Giulio Superti-Furga; “Paralog-dependent isogenic cell assay cascade generates highly selective SLC16A3 inhibitors”; Cell Chemical Biology, 2023.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
